Overview

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

This is an open label investigator initiated Phase Ib study of combination pembrolizumab (Keytruda), 200mg IV 3 weekly (Q3W) with 50mg oral cyclophosphamide daily (OD) in metastatic renal cell carcinoma patients. 21 patients will be recruited within the United Kingdom (UK) will to examine the efficacy of the combination for up to 35 administrations (2 years). This study will be conducted in compliance with Good Clinical Practice (GCP) and all relevant regulations.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

The Christie NHS Foundation Trust

Collaborators:

Liverpool Clinical Trials Centre (LCTC), University of Liverpool
Merck Sharp & Dohme Corp.
University of Manchester

Treatments:

Cyclophosphamide
Pembrolizumab